INAMED'S JUVEDERM DATA TO BE PRESENTED AT CONFERENCE

Inamed has announced that Phase III clinical data for the three formulations of Juvederm (Juvederm 24HV, Juvederm 30HV, and Juvederm 30), a next generation, non-animal, cross linked hyaluronic acid based dermal filler, will be presented at the 64th Annual Meeting of the American Academy of Dermatology in San Francisco, Calif. The data shows superior efficacy and duration of effect versus Zyplast (cross-linked bovine collagen).

Based on the independent investigators' assessments, the percent of patients that had improved with Juvederm at six months was in the range of 81 percent to 90 percent, versus 36 percent to 45 percent for Zyplast.